Last reviewed · How we verify

Blood Stopper (Ankaferd)

Ankara Ataturk Sanatorium Training and Research Hospital · FDA-approved active Small molecule

Blood Stopper (Ankaferd) is a Topical hemostatic agent Small molecule drug developed by Ankara Ataturk Sanatorium Training and Research Hospital. It is currently FDA-approved for Control of bleeding in surgical procedures, Epistaxis (nosebleeds), Oral bleeding and dental procedures.

Ankaferd Blood Stopper is a topical hemostatic agent that promotes rapid blood clotting through a combination of plant-derived proteins and minerals that enhance the coagulation cascade.

Ankaferd Blood Stopper is a topical hemostatic agent that promotes rapid blood clotting through a combination of plant-derived proteins and minerals that enhance the coagulation cascade. Used for Control of bleeding in surgical procedures, Epistaxis (nosebleeds), Oral bleeding and dental procedures.

At a glance

Generic nameBlood Stopper (Ankaferd)
SponsorAnkara Ataturk Sanatorium Training and Research Hospital
Drug classTopical hemostatic agent
ModalitySmall molecule
Therapeutic areaHemostasis / Surgery
PhaseFDA-approved

Mechanism of action

The product contains a proprietary blend of plant extracts (including Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica) along with minerals that work synergistically to activate the intrinsic coagulation pathway and promote platelet aggregation. It creates a protein network that facilitates clot formation at the site of bleeding without systemic anticoagulation effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Blood Stopper (Ankaferd)

What is Blood Stopper (Ankaferd)?

Blood Stopper (Ankaferd) is a Topical hemostatic agent drug developed by Ankara Ataturk Sanatorium Training and Research Hospital, indicated for Control of bleeding in surgical procedures, Epistaxis (nosebleeds), Oral bleeding and dental procedures.

How does Blood Stopper (Ankaferd) work?

Ankaferd Blood Stopper is a topical hemostatic agent that promotes rapid blood clotting through a combination of plant-derived proteins and minerals that enhance the coagulation cascade.

What is Blood Stopper (Ankaferd) used for?

Blood Stopper (Ankaferd) is indicated for Control of bleeding in surgical procedures, Epistaxis (nosebleeds), Oral bleeding and dental procedures, Dermatological bleeding.

Who makes Blood Stopper (Ankaferd)?

Blood Stopper (Ankaferd) is developed and marketed by Ankara Ataturk Sanatorium Training and Research Hospital (see full Ankara Ataturk Sanatorium Training and Research Hospital pipeline at /company/ankara-ataturk-sanatorium-training-and-research-hospital).

What drug class is Blood Stopper (Ankaferd) in?

Blood Stopper (Ankaferd) belongs to the Topical hemostatic agent class. See all Topical hemostatic agent drugs at /class/topical-hemostatic-agent.

What development phase is Blood Stopper (Ankaferd) in?

Blood Stopper (Ankaferd) is FDA-approved (marketed).

What are the side effects of Blood Stopper (Ankaferd)?

Common side effects of Blood Stopper (Ankaferd) include Local irritation or burning sensation, Allergic reaction to plant components.

Related